MedTrace Logo

Mobile-Directly Observed Therapy on Adherence to Hydroxyurea

NCT02844673 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2024-06-12

No results posted yet for this study

Summary

To examine the effect of mobile-directly observed therapy (mDOT) on adherence to HU (mDOT-HuA) adults with SCA at Muhimbili National Hospital (MNH) in Tanzania.

Conditions

  • Sickle Cell Anaemia

Interventions

DRUG

Hydroxyurea

Patients will receive fixed dose Hydroxyurea therapy (15 mg/Kg/day) with standard monitoring

DEVICE

Mobile Directly Observed Therapy

Mobile DOT will consist of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Patients will receive alerts on their cell phone at pre-arranged times to remind them to take their medications.

Sponsors & Collaborators

  • University of Pittsburgh

    collaborator OTHER

  • Muhimbili National Hospital

    collaborator UNKNOWN

  • Muhimbili University of Health and Allied Sciences

    lead OTHER

Principal Investigators

  • Julie Makani, PhD · Muhimbili University of Health and Allied Sciences

  • Abel Makubi, MMed · Muhimbili University of Health and Allied Sciences

  • Philip Sasi, PhD · Muhimbili University of Health and Allied Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-28
Primary Completion
2018-01-28
Completion
2018-05-18

Countries

  • Tanzania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02844673 on ClinicalTrials.gov